Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Recher

Showing results (291-300 of 488) with videos related to

Pageof 49
Sort By:
Pharmaceutics|April 23, 2022
Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 TrialGuillaume Drevin, Marie Briet, Caroline Bazzoli, et al.
European Journal of Immunology|August 5, 2010
Oxidized ATP inhibits T-cell-mediated autoimmunityPhilipp A Lang, Doron Merkler, Pauline Funkner, et al.
World Journal of Pediatrics : WJP|March 20, 2024
Severe acute respiratory syndrome coronavirus-2-related and imputable deaths in children: results from the French pediatric national registryMarguerite Lockhart-Bouron, Noémie Vanel, Michael Levy, et al.
Future Oncology (London, England)|November 19, 2025
Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed <i>IDH1</i> mutant AMLSamantha Nier, Jana Pelouchova, Ralph Hills, et al.
Future Oncology (London, England)|November 16, 2025
ALIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed <i>IDH1</i> mutant acute myeloid leukemiaParesh Vyas, Sam Salek, Susana Vives, et al.
Genes, Chromosomes & Cancer|December 13, 2005
EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangementsBruce Poppe, Nicole Dastugue, Jo Vandesompele, et al.
Leukemia|April 7, 2011
Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidineR Itzykson, S Thépot, V Eclache, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 13, 2006
Increased susceptibility to bacterial superinfection as a consequence of innate antiviral responsesAlexander A Navarini, Mike Recher, Karl S Lang, et al.
International Journal of Clinical Pharmacy|July 12, 2011
Induction-related cost of patients with acute myeloid leukaemia in FranceVirginie Nerich, Bruno Lioure, Maryline Rave, et al.
Hematological Oncology|October 15, 2014
Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme+ T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosisStanislas Faguer, François Vergez, Michael Peres, et al.
Pageof 49

Showing results (291-300 of 488) with videos related to

Sort By:
Pageof 49
Pharmaceutics|April 23, 2022
Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 TrialGuillaume Drevin, Marie Briet, Caroline Bazzoli, et al.
European Journal of Immunology|August 5, 2010
Oxidized ATP inhibits T-cell-mediated autoimmunityPhilipp A Lang, Doron Merkler, Pauline Funkner, et al.
World Journal of Pediatrics : WJP|March 20, 2024
Severe acute respiratory syndrome coronavirus-2-related and imputable deaths in children: results from the French pediatric national registryMarguerite Lockhart-Bouron, Noémie Vanel, Michael Levy, et al.
Future Oncology (London, England)|November 19, 2025
Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed <i>IDH1</i> mutant AMLSamantha Nier, Jana Pelouchova, Ralph Hills, et al.
Future Oncology (London, England)|November 16, 2025
ALIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed <i>IDH1</i> mutant acute myeloid leukemiaParesh Vyas, Sam Salek, Susana Vives, et al.
Genes, Chromosomes & Cancer|December 13, 2005
EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangementsBruce Poppe, Nicole Dastugue, Jo Vandesompele, et al.
Leukemia|April 7, 2011
Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidineR Itzykson, S Thépot, V Eclache, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 13, 2006
Increased susceptibility to bacterial superinfection as a consequence of innate antiviral responsesAlexander A Navarini, Mike Recher, Karl S Lang, et al.
International Journal of Clinical Pharmacy|July 12, 2011
Induction-related cost of patients with acute myeloid leukaemia in FranceVirginie Nerich, Bruno Lioure, Maryline Rave, et al.
Hematological Oncology|October 15, 2014
Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme+ T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosisStanislas Faguer, François Vergez, Michael Peres, et al.
Pageof 49